Biocorrx Inc Stock Price, News & Analysis

BioCorRx Inc. (OTCQB: BICX) announced the receipt of a $100,000 supplemental grant from the National Institute on Drug Abuse for the first-in-human clinical trial of BICX104, a biodegradable naltrexone pellet aimed at treating opioid use disorder. This grant contributes to the nearly $9.3 million in non-dilutive funding received from NIH/NIDA. BICX104 benefits from active Investigational New Drug status and a favorable FDA review pathway. The funding will enhance data sharing and support further clinical development of the medication.

BioCorRx (BICX) provided a 2021 year-end business update highlighting several key milestones. The company received FDA clearance for human trials of BICX104, an implantable pellet targeting opioid use disorder. A major achievement included a $3.5 million grant from NIDA, contributing to nearly $9.2 million in non-dilutive funding. Furthermore, intellectual property expansion includes a patent acquisition and a newly filed patent application for BICX104. The company is set to begin first-in-human trials in Q2 2022, aiming for improved compliance and outcomes in treating opioid use disorder.

BioCorRx Inc. (OTCQB: BICX) has announced its participation in two significant conferences: the 2022 Virtual Growth Conference from March 28-30 and the ASAM 53rd Annual Conference from March 31 to April 3. The Virtual Growth Conference, hosted by Maxim Group LLC, features various presentations and discussions aimed at fostering growth. Meanwhile, the ASAM conference in Hollywood, FL, will showcase advancements in addiction medicine, where BioCorRx Pharmaceuticals will exhibit at booth 306. The company specializes in innovative substance abuse treatment programs.

BioCorRx Inc. (OTCQB: BICX) has received Independent Institutional Review Board (IRB) approval for its Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet aimed at treating opioid use disorder (OUD). This approval is a significant milestone, allowing the company to initiate first-in-human trials. The trial, involving 24 healthy volunteers, will compare BICX104 to marketed naltrexone injections. The company is collaborating with the National Institute on Drug Abuse and aims to enhance patient compliance to naltrexone therapy, potentially improving outcomes in addiction treatment.

BioCorRx Inc. (OTCQB: BICX) announced the completion of a clinical trial agreement with Orange County Research Center for its first-in-human trial of BICX104, a biodegradable naltrexone pellet aimed at treating opioid use disorder (OUD). This collaboration, led by Dr. Joel M. Neutel, signifies a major milestone for BioCorRx, as they seek FDA approval for the pellet. The trial is expected to commence once clinical samples are ready and participants are recruited. BICX104 is being developed with the National Institute on Drug Abuse, providing potential dual indications for OUD and Alcohol Use Disorder.

BioCorRx Inc. (OTCQB: BICX) announced that CEO Lourdes Felix and President Brady Granier will present at the H.C. Wainwright BioConnect 2022 Conference, scheduled for January 10-13, 2022. The presentation will be available on-demand starting January 10, 2022, at 7:00 AM ET. BioCorRx is focused on innovative treatment solutions for substance abuse, including the Beat Addiction Recovery program and the UnCraveRx® Weight Loss Program. The company also seeks FDA approval for BICX104, an implantable naltrexone pellet for treating alcohol and opioid use disorders.

BioCorRx Inc. (OTCQB: BICX) has appointed Dr. Jie Shen to its Scientific Advisory Board (SAB). Dr. Shen brings expertise in drug delivery systems and has previously worked on formulations for naltrexone, crucial for advancing BICX104, an implantable naltrexone pellet aimed at treating opioid use disorder. CEO Lourdes Felix emphasized the significance of Dr. Shen’s experience in enhancing BioCorRx's capabilities as it progresses towards human trials. BioCorRx is focused on innovative addiction treatment solutions and currently seeks FDA approval for BICX104.

BioCorRx Inc. (OTCQB: BICX) announced that CEO Lourdes Felix and President Brady Granier will present at the Benzinga All Access event on December 2, 2021, at 11:00 A.M. Eastern Time. The event will be streamed live, and an archived recording will be available on the company's investor relations website. BioCorRx specializes in innovative treatment programs for substance abuse, including the Beat Addiction Recovery program and the UnCraveRx® Weight Loss Program. The company is also developing BICX104, an implantable naltrexone pellet aimed at treating alcohol and opioid use disorders.

BioCorRx Inc. (OTCQB: BICX) announced the acquisition of a patent application from Calista Therapeutics covering a solid implant formulation for drug delivery. This patent, application number 17/465,748, may enhance current naltrexone formulations and is expected to add value to BioCorRx's existing intellectual property portfolio. CEO Lourdes Felix expressed excitement over the potential improvements in drug delivery systems, which could benefit the company’s treatment programs for substance abuse and related disorders.